Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients
Acta Oncol. 2021 Mar 3:1-5. doi: 10.1080/0284186X.2021.1892820. Online ahead of print.NO ABSTRACTPMID:33656957 | DOI:10.1080/0284186X.2021.1892820 (Source: Acta Oncologica)
Source: Acta Oncologica - March 3, 2021 Category: Cancer & Oncology Authors: Mikko Vuoristo Timo Muhonen Virve Koljonen Susanna Juteau Micaela Hernberg Suvi Ilmonen Tiina Jahkola Source Type: research

Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients
Acta Oncol. 2021 Mar 3:1-5. doi: 10.1080/0284186X.2021.1892820. Online ahead of print.NO ABSTRACTPMID:33656957 | DOI:10.1080/0284186X.2021.1892820 (Source: Acta Oncologica)
Source: Acta Oncologica - March 3, 2021 Category: Cancer & Oncology Authors: Mikko Vuoristo Timo Muhonen Virve Koljonen Susanna Juteau Micaela Hernberg Suvi Ilmonen Tiina Jahkola Source Type: research

Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients
Acta Oncol. 2021 Mar 3:1-5. doi: 10.1080/0284186X.2021.1892820. Online ahead of print.NO ABSTRACTPMID:33656957 | DOI:10.1080/0284186X.2021.1892820 (Source: Acta Oncologica)
Source: Acta Oncologica - March 3, 2021 Category: Cancer & Oncology Authors: Mikko Vuoristo Timo Muhonen Virve Koljonen Susanna Juteau Micaela Hernberg Suvi Ilmonen Tiina Jahkola Source Type: research

End-of-life anticancer treatment - a nationwide registry-based study of trends in the use of chemo-, endocrine, immune-, and targeted therapies
CONCLUSIONS: We found a stable overall rate at 16% of patients receiving anticancer treatment within one month prior to death in this nationwide sample of cancer deaths. Further research is needed to assess whether this level of end-of-life treatment is justified or reflects inappropriate use.PMID:33651643 | DOI:10.1080/0284186X.2021.1890332 (Source: Acta Oncologica)
Source: Acta Oncologica - March 2, 2021 Category: Cancer & Oncology Authors: Thea Otto Mattsson Anton Potteg ård Trine Lembrecht J ørgensen Anders Green Mette Bliddal Source Type: research

The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness
CONCLUSION: Active use of PROMs did not improve patients' experience of involvement in follow-up care as compared to passive use.PMID:33651647 | DOI:10.1080/0284186X.2021.1891281 (Source: Acta Oncologica)
Source: Acta Oncologica - March 2, 2021 Category: Cancer & Oncology Authors: Anette Stolberg Kargo Pernille Tine Jensen Kristina Lindemann Niels Henrik Ingvar Hjollund Bente Lund Mette Haee S ören Möller Dorte Gils å Hansen Karina Dahl Steffensen Source Type: research

Research in radiation oncology and the Covid-19 pandemic
Acta Oncol. 2021 Mar 2:1-2. doi: 10.1080/0284186X.2021.1890334. Online ahead of print.NO ABSTRACTPMID:33651648 | DOI:10.1080/0284186X.2021.1890334 (Source: Acta Oncologica)
Source: Acta Oncologica - March 2, 2021 Category: Cancer & Oncology Authors: Morten H øyer Cai Grau Source Type: research

End-of-life anticancer treatment - a nationwide registry-based study of trends in the use of chemo-, endocrine, immune-, and targeted therapies
CONCLUSIONS: We found a stable overall rate at 16% of patients receiving anticancer treatment within one month prior to death in this nationwide sample of cancer deaths. Further research is needed to assess whether this level of end-of-life treatment is justified or reflects inappropriate use.PMID:33651643 | DOI:10.1080/0284186X.2021.1890332 (Source: Acta Oncologica)
Source: Acta Oncologica - March 2, 2021 Category: Cancer & Oncology Authors: Thea Otto Mattsson Anton Potteg ård Trine Lembrecht J ørgensen Anders Green Mette Bliddal Source Type: research

The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness
CONCLUSION: Active use of PROMs did not improve patients' experience of involvement in follow-up care as compared to passive use.PMID:33651647 | DOI:10.1080/0284186X.2021.1891281 (Source: Acta Oncologica)
Source: Acta Oncologica - March 2, 2021 Category: Cancer & Oncology Authors: Anette Stolberg Kargo Pernille Tine Jensen Kristina Lindemann Niels Henrik Ingvar Hjollund Bente Lund Mette Haee S ören Möller Dorte Gils å Hansen Karina Dahl Steffensen Source Type: research

Research in radiation oncology and the Covid-19 pandemic
Acta Oncol. 2021 Mar 2:1-2. doi: 10.1080/0284186X.2021.1890334. Online ahead of print.NO ABSTRACTPMID:33651648 | DOI:10.1080/0284186X.2021.1890334 (Source: Acta Oncologica)
Source: Acta Oncologica - March 2, 2021 Category: Cancer & Oncology Authors: Morten H øyer Cai Grau Source Type: research

Patient reported outcomes interfering with daily activities in prostate cancer patients receiving antineoplastic treatment
CONCLUSION: PRO may help inform caregivers about symptoms not previously reported, interfering with usual or daily activities but also point to the use of this information to inform new patients. This may help clinicians and patients decide a treatment plan with an acceptable benefit-to-harm ratio.PMID:33641578 | DOI:10.1080/0284186X.2021.1881818 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Dag Rune Stormoen Christina Baeksted Gry Assam Taarnh øj Christoffer Johansen Helle Pappot Source Type: research

Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer
CONCLUSION: SBRT alone to multiple lung tumors with SPLC results in comparable PFS, OS, and LF rates to a cohort of patients treated for solitary early stage NSCLC. Those with SPLC had non-significantly higher R/DF. Patients with SPLC should be followed closely for failure and possible salvage therapy.PMID:33645424 | DOI:10.1080/0284186X.2021.1892182 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Cole R Steber Ryan T Hughes Michael H Soike Corbin A Helis Karina Nieto Travis Jacobson Moeko Nagatsuka Hamilton S McGinnis C Marc Leyrer Michael K Farris Source Type: research

Is proton beam therapy ready for single fraction spine SBRS? - a feasibility study to use spot-scanning proton arc (SPArc) therapy to improve the robustness and dosimetric plan quality
Acta Oncol. 2021 Feb 27:1-5. doi: 10.1080/0284186X.2021.1892183. Online ahead of print.NO ABSTRACTPMID:33645429 | DOI:10.1080/0284186X.2021.1892183 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Gang Liu Xiaoqiang Li An Qin Jun Zhou Weili Zheng Lewei Zhao Jun Han Sheng Zhang Di Yan Craig Stevens Inga Grills Xuanfeng Ding Source Type: research

Anatomically robust proton therapy using multiple planning computed tomography scans for locally advanced prostate cancer
CONCLUSIONS: While both proton plans reduced the low-to-intermediate normal tissue doses compared to VMAT, ARPT plans improved the target coverage for the most challenging patient without significantly increasing the normal tissue doses compared to conventional robust PT plans.PMID:33646069 | DOI:10.1080/0284186X.2021.1892181 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Kia Busch Benjamin Dahl Stine E Petersen Heidi S R ønde Lise Bentzen Sara Pilskog Ludvig P Muren Source Type: research

Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study
CONCLUSIONS: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.HighlightsAge, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.Recent cytotoxic therapy, however, did not seem to...
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: S Ehmsen L H Jakobsen M E Lendorf R L Eefsen L Bentsen A S Knoop N Aggerholm-Pedersen H Skuladottir J Herrstedt L H Jensen C Rotb øl M B Damm K Wedervang A Glenth øj J Ryg H Frederiksen A R Kodahl Source Type: research

Look at the compass needle and see your course - navigation as a cancer survivor
Acta Oncol. 2021 Mar 1:1-2. doi: 10.1080/0284186X.2021.1893381. Online ahead of print.NO ABSTRACTPMID:33646072 | DOI:10.1080/0284186X.2021.1893381 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Christoffer Johansen Susanne O Dalton Source Type: research

Correction
Acta Oncol. 2021 Mar 1:1-3. doi: 10.1080/0284186X.2021.1885873. Online ahead of print.NO ABSTRACTPMID:33646082 | DOI:10.1080/0284186X.2021.1885873 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Source Type: research

Paediatric-type follicular lymphoma arising in conjunction with pregnancy
Acta Oncol. 2021 Mar 1:1-2. doi: 10.1080/0284186X.2021.1882698. Online ahead of print.NO ABSTRACTPMID:33646929 | DOI:10.1080/0284186X.2021.1882698 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Stefano Fratoni Pasquale Niscola Source Type: research

Patient reported outcomes interfering with daily activities in prostate cancer patients receiving antineoplastic treatment
CONCLUSION: PRO may help inform caregivers about symptoms not previously reported, interfering with usual or daily activities but also point to the use of this information to inform new patients. This may help clinicians and patients decide a treatment plan with an acceptable benefit-to-harm ratio.PMID:33641578 | DOI:10.1080/0284186X.2021.1881818 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Dag Rune Stormoen Christina Baeksted Gry Assam Taarnh øj Christoffer Johansen Helle Pappot Source Type: research

Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer
CONCLUSION: SBRT alone to multiple lung tumors with SPLC results in comparable PFS, OS, and LF rates to a cohort of patients treated for solitary early stage NSCLC. Those with SPLC had non-significantly higher R/DF. Patients with SPLC should be followed closely for failure and possible salvage therapy.PMID:33645424 | DOI:10.1080/0284186X.2021.1892182 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Cole R Steber Ryan T Hughes Michael H Soike Corbin A Helis Karina Nieto Travis Jacobson Moeko Nagatsuka Hamilton S McGinnis C Marc Leyrer Michael K Farris Source Type: research

Is proton beam therapy ready for single fraction spine SBRS? - a feasibility study to use spot-scanning proton arc (SPArc) therapy to improve the robustness and dosimetric plan quality
Acta Oncol. 2021 Feb 27:1-5. doi: 10.1080/0284186X.2021.1892183. Online ahead of print.NO ABSTRACTPMID:33645429 | DOI:10.1080/0284186X.2021.1892183 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Gang Liu Xiaoqiang Li An Qin Jun Zhou Weili Zheng Lewei Zhao Jun Han Sheng Zhang Di Yan Craig Stevens Inga Grills Xuanfeng Ding Source Type: research

Anatomically robust proton therapy using multiple planning computed tomography scans for locally advanced prostate cancer
CONCLUSIONS: While both proton plans reduced the low-to-intermediate normal tissue doses compared to VMAT, ARPT plans improved the target coverage for the most challenging patient without significantly increasing the normal tissue doses compared to conventional robust PT plans.PMID:33646069 | DOI:10.1080/0284186X.2021.1892181 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Kia Busch Benjamin Dahl Stine E Petersen Heidi S R ønde Lise Bentzen Sara Pilskog Ludvig P Muren Source Type: research

Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study
CONCLUSIONS: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.HighlightsAge, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.Recent cytotoxic therapy, however, did not seem to...
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: S Ehmsen L H Jakobsen M E Lendorf R L Eefsen L Bentsen A S Knoop N Aggerholm-Pedersen H Skuladottir J Herrstedt L H Jensen C Rotb øl M B Damm K Wedervang A Glenth øj J Ryg H Frederiksen A R Kodahl Source Type: research

Look at the compass needle and see your course - navigation as a cancer survivor
Acta Oncol. 2021 Mar 1:1-2. doi: 10.1080/0284186X.2021.1893381. Online ahead of print.NO ABSTRACTPMID:33646072 | DOI:10.1080/0284186X.2021.1893381 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: Christoffer Johansen Susanne O Dalton Source Type: research

Correction
Acta Oncol. 2021 Mar 1:1-3. doi: 10.1080/0284186X.2021.1885873. Online ahead of print.NO ABSTRACTPMID:33646082 | DOI:10.1080/0284186X.2021.1885873 (Source: Acta Oncologica)
Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Source Type: research

Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience
Acta Oncol. 2021 Feb 25:1-4. doi: 10.1080/0284186X.2021.1887516. Online ahead of print.NO ABSTRACTPMID:33629926 | DOI:10.1080/0284186X.2021.1887516 (Source: Acta Oncologica)
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: Mary McGunigal Marc Margolis Matthew Forsthoefel Tanvee Singh Katherine Amarell David Deblois Lloyd Campbell Chul Kim Stephen Liu Peter J Bergquist Pedro Debrito Brian T Collins Giuseppe Giaccone Jonathan W Lischalk Source Type: research

Prospective study for establishing minimal clinically important differences in patients with surgery for lower extremity metastases
CONCLUSION: This prospective study successfully defined a MCID for PROMIS Pain Interference of 7.5 (3.4-12), PROMIS Physical Function of 4.1 (0.6-7.6), and Global Physical Health of 4.2 (2.0-6.6) in patients with (impending) pathological fractures due to osseous metastases in the lower extremity; no MCID could be established for PROMIS Global Mental Health. Defining a narrower MCID value for each subpopulation requires a large, prospective, multicenter study. Nevertheless, the provided MCID values allow guidance to clinicians to evaluate the impact of surgical treatment on a patient's QoL.LEVEL OF EVIDENCE: Level II Diagno...
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: M E R Bongers O Q Groot Q C B S Thio J A M Bramer J J Verlaan E T Newman K A Raskin S A Lozano-Calderon J H Schwab Source Type: research

Meta-analysis of BCOR rearranged sarcomas: challenging the therapeutic approach
CONCLUSION: Our data support that non-Ewing treatment strategy can be considered a safe option, being at least equal to Ewing protocols. The current study provides a hint toward the optimal therapeutic approach of BCOR rearranged sarcomas. Further, the present study challenges the use of the term Ewing-like sarcomas, since the current literature supports that BCOR rearranged sarcomas deserve their own distinct classification in terms of genetics, pathology and therapy.PMID:33630701 | DOI:10.1080/0284186X.2021.1890818 (Source: Acta Oncologica)
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: Anastasios Kyriazoglou Pantelis Bagos Source Type: research

Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience
Acta Oncol. 2021 Feb 25:1-4. doi: 10.1080/0284186X.2021.1887516. Online ahead of print.NO ABSTRACTPMID:33629926 | DOI:10.1080/0284186X.2021.1887516 (Source: Acta Oncologica)
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: Mary McGunigal Marc Margolis Matthew Forsthoefel Tanvee Singh Katherine Amarell David Deblois Lloyd Campbell Chul Kim Stephen Liu Peter J Bergquist Pedro Debrito Brian T Collins Giuseppe Giaccone Jonathan W Lischalk Source Type: research

Prospective study for establishing minimal clinically important differences in patients with surgery for lower extremity metastases
CONCLUSION: This prospective study successfully defined a MCID for PROMIS Pain Interference of 7.5 (3.4-12), PROMIS Physical Function of 4.1 (0.6-7.6), and Global Physical Health of 4.2 (2.0-6.6) in patients with (impending) pathological fractures due to osseous metastases in the lower extremity; no MCID could be established for PROMIS Global Mental Health. Defining a narrower MCID value for each subpopulation requires a large, prospective, multicenter study. Nevertheless, the provided MCID values allow guidance to clinicians to evaluate the impact of surgical treatment on a patient's QoL.LEVEL OF EVIDENCE: Level II Diagno...
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: M E R Bongers O Q Groot Q C B S Thio J A M Bramer J J Verlaan E T Newman K A Raskin S A Lozano-Calderon J H Schwab Source Type: research

Meta-analysis of BCOR rearranged sarcomas: challenging the therapeutic approach
CONCLUSION: Our data support that non-Ewing treatment strategy can be considered a safe option, being at least equal to Ewing protocols. The current study provides a hint toward the optimal therapeutic approach of BCOR rearranged sarcomas. Further, the present study challenges the use of the term Ewing-like sarcomas, since the current literature supports that BCOR rearranged sarcomas deserve their own distinct classification in terms of genetics, pathology and therapy.PMID:33630701 | DOI:10.1080/0284186X.2021.1890818 (Source: Acta Oncologica)
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: Anastasios Kyriazoglou Pantelis Bagos Source Type: research

Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience
Acta Oncol. 2021 Feb 25:1-4. doi: 10.1080/0284186X.2021.1887516. Online ahead of print.NO ABSTRACTPMID:33629926 | DOI:10.1080/0284186X.2021.1887516 (Source: Acta Oncologica)
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: Mary McGunigal Marc Margolis Matthew Forsthoefel Tanvee Singh Katherine Amarell David Deblois Lloyd Campbell Chul Kim Stephen Liu Peter J Bergquist Pedro Debrito Brian T Collins Giuseppe Giaccone Jonathan W Lischalk Source Type: research

Prospective study for establishing minimal clinically important differences in patients with surgery for lower extremity metastases
CONCLUSION: This prospective study successfully defined a MCID for PROMIS Pain Interference of 7.5 (3.4-12), PROMIS Physical Function of 4.1 (0.6-7.6), and Global Physical Health of 4.2 (2.0-6.6) in patients with (impending) pathological fractures due to osseous metastases in the lower extremity; no MCID could be established for PROMIS Global Mental Health. Defining a narrower MCID value for each subpopulation requires a large, prospective, multicenter study. Nevertheless, the provided MCID values allow guidance to clinicians to evaluate the impact of surgical treatment on a patient's QoL.LEVEL OF EVIDENCE: Level II Diagno...
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: M E R Bongers O Q Groot Q C B S Thio J A M Bramer J J Verlaan E T Newman K A Raskin S A Lozano-Calderon J H Schwab Source Type: research

Meta-analysis of BCOR rearranged sarcomas: challenging the therapeutic approach
CONCLUSION: Our data support that non-Ewing treatment strategy can be considered a safe option, being at least equal to Ewing protocols. The current study provides a hint toward the optimal therapeutic approach of BCOR rearranged sarcomas. Further, the present study challenges the use of the term Ewing-like sarcomas, since the current literature supports that BCOR rearranged sarcomas deserve their own distinct classification in terms of genetics, pathology and therapy.PMID:33630701 | DOI:10.1080/0284186X.2021.1890818 (Source: Acta Oncologica)
Source: Acta Oncologica - February 25, 2021 Category: Cancer & Oncology Authors: Anastasios Kyriazoglou Pantelis Bagos Source Type: research

Primary pericardial mesothelioma: a case report of a patient treated with an immune checkpoint inhibitor as the second-line treatment
Acta Oncol. 2021 Feb 23:1-5. doi: 10.1080/0284186X.2021.1887515. Online ahead of print.NO ABSTRACTPMID:33620252 | DOI:10.1080/0284186X.2021.1887515 (Source: Acta Oncologica)
Source: Acta Oncologica - February 23, 2021 Category: Cancer & Oncology Authors: Otso Arponen Virpi Salo Annika L önnberg Leila Vaalavirta Hannu Koivu Paul Nyandoto Source Type: research

Primary pericardial mesothelioma: a case report of a patient treated with an immune checkpoint inhibitor as the second-line treatment
Acta Oncol. 2021 Feb 23:1-5. doi: 10.1080/0284186X.2021.1887515. Online ahead of print.NO ABSTRACTPMID:33620252 | DOI:10.1080/0284186X.2021.1887515 (Source: Acta Oncologica)
Source: Acta Oncologica - February 23, 2021 Category: Cancer & Oncology Authors: Otso Arponen Virpi Salo Annika L önnberg Leila Vaalavirta Hannu Koivu Paul Nyandoto Source Type: research

Primary pericardial mesothelioma: a case report of a patient treated with an immune checkpoint inhibitor as the second-line treatment
Acta Oncol. 2021 Feb 23:1-5. doi: 10.1080/0284186X.2021.1887515. Online ahead of print.NO ABSTRACTPMID:33620252 | DOI:10.1080/0284186X.2021.1887515 (Source: Acta Oncologica)
Source: Acta Oncologica - February 23, 2021 Category: Cancer & Oncology Authors: Otso Arponen Virpi Salo Annika L önnberg Leila Vaalavirta Hannu Koivu Paul Nyandoto Source Type: research

Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab'
Acta Oncol. 2021 Feb 20:1-3. doi: 10.1080/0284186X.2021.1889028. Online ahead of print.NO ABSTRACTPMID:33612057 | DOI:10.1080/0284186X.2021.1889028 (Source: Acta Oncologica)
Source: Acta Oncologica - February 22, 2021 Category: Cancer & Oncology Authors: Mehmet Zahid Kocak Source Type: research

Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity?
Acta Oncol. 2021 Feb 22:1-8. doi: 10.1080/0284186X.2021.1887514. Online ahead of print.ABSTRACTBACKGROUND: Cisplatin-based chemotherapy (CBCT) can cause high-frequency hearing loss, but little is known about the development and clinical relevance of this hearing loss in survivors of adult-onset cancer with very long-term follow-up. This case-control study investigates hearing and speech perception both in quiet and with background noise 30-years after CBCT.PATIENTS AND METHODS: One-hundred-and-one patients (Cases) who received CBCT for testicular cancer between 1980 and 1994 were assessed with pure-tone audiometry (.125 - ...
Source: Acta Oncologica - February 22, 2021 Category: Cancer & Oncology Authors: J Skalleberg M Myhrum M C Sm åstuen T A Osnes S D Foss å M Bunne Source Type: research

Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden
CONCLUSION: 1,310 men were treated with abiraterone and 3,579 with enzalutamide. In multivariable analysis, CVD risk was increased in men on abiraterone (hazard ratio (HR): 1.19; 95% confidence interval (CI): 1.03-1.38) and in men on enzalutamide (HR: 1.10; 95% CI: 1.01-1.20). Men with a recent CVD (
Source: Acta Oncologica - February 19, 2021 Category: Cancer & Oncology Authors: Gincy George Hanna Vikman Rolf Gedeborg Ingela Franck Lissbrant Hans Garmo Johan Styrke Mieke Van Hemelrijck P är Stattin Source Type: research

Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.
CONCLUSION: 1,310 men were treated with abiraterone and 3,579 with enzalutamide. In multivariable analysis, CVD risk was increased in men on abiraterone (hazard ratio (HR): 1.19; 95% confidence interval (CI): 1.03-1.38) and in men on enzalutamide (HR: 1.10; 95% CI: 1.01-1.20). Men with a recent CVD (
Source: Acta Oncologica - February 19, 2021 Category: Cancer & Oncology Authors: George G, Vikman H, Gedeborg R, Lissbrant IF, Garmo H, Styrke J, Van Hemelrijck M, Stattin P Tags: Acta Oncol Source Type: research

Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis.
CONCLUSION: This systematic review demonstrates that a higher dose of bladder RT was not associated with improved response rates of hematuria and frequency symptoms but was associated with reduced response of dysuria. Higher doses of bladder RT was associated with more durable hematuria response. Prospective studies to determine the effects of palliative bladder radiotherapy on HRQOL outcomes are warranted. PMID: 33591843 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 16, 2021 Category: Cancer & Oncology Authors: Tey J, Ho F, Koh WY, Chia D, Ooi KH, Tuan JKL, Vellayappan B, Soon YY Tags: Acta Oncol Source Type: research

Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses.
CONCLUSION: NLR has a significant prognostic value in urological tumors and should be included in prognostic scores of these cancers. PMID: 33586577 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 15, 2021 Category: Cancer & Oncology Authors: Mjaess G, Chebel R, Karam A, Moussa I, Pretot D, Abi Tayeh G, Sarkis J, Semaan A, Peltier A, Aoun F, Albisinni S, Roumeguère T Tags: Acta Oncol Source Type: research

Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins.
CONCLUSIONS: Although no independent survival benefit was observed, the point estimates favoured adjuvant treatment, predominantly in patients with chemo-responsive tumours. PMID: 33586602 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 15, 2021 Category: Cancer & Oncology Authors: Bott RK, Beckmann K, Zylstra J, Wilkinson MJ, Knight WRC, Baker CR, Kelly M, Maisey N, Waters J, Van Hemelrijck M, Smyth EC, Allum WH, Lagergren J, Gossage JA, Cunningham D, Davies AR Tags: Acta Oncol Source Type: research

Correlation and prognostic impact of human papilloma virus and p16-expression in advanced hypopharynx and larynx cancer treated with definitive radiotherapy.
PMID: 33583307 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 13, 2021 Category: Cancer & Oncology Authors: Lassen P, Schou M, Overgaard J, Alsner J Tags: Acta Oncol Source Type: research

Two cases of rare late onset life-threatening pseudoprogression with immune check point inhibitors in advanced cancer patients - a case report.
PMID: 33583310 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 13, 2021 Category: Cancer & Oncology Authors: Coudert V, Robin YM, Tessier W, Forestier A, Penel N Tags: Acta Oncol Source Type: research

Taxane-induced pain in breast cancer patients as perceived by nurses.
Conclusion: This study highlights a need for attention to education and guidelines for how to observe, treat, and evaluate this particular type of pain. PMID: 33567934 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 10, 2021 Category: Cancer & Oncology Authors: Hellerstedt-Börjesson S, Nordin K, Fjällskog ML, Peterson M, Arving C Tags: Acta Oncol Source Type: research

Approval of new drugs in oncology - a changing pattern.
PMID: 33550899 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 8, 2021 Category: Cancer & Oncology Authors: Hagberg H Tags: Acta Oncol Source Type: research

Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA.
CONCLUSIONS: Guideline compliance and a combined treatment approach reduced the incidence of LRF and thereby increased OS. Our results confirm those of international studies. Treatment of sinonasal carcinoma remains a challenge that requires multidisciplinary team coordination. PMID: 33544640 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 5, 2021 Category: Cancer & Oncology Authors: Filtenborg MV, Lilja-Fischer JK, Sharma MB, Primdahl H, Kjems J, Plaschke CC, Wessel I, Kristensen CA, Andersen M, Andersen E, Godballe C, Johansen J, Overgaard J, Petersen KB Tags: Acta Oncol Source Type: research

Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban community.
PMID: 33522846 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 1, 2021 Category: Cancer & Oncology Authors: Ngo T, Hossain C, Guzman AK, Halmos B, Balagula Y, McLellan B Tags: Acta Oncol Source Type: research

A comparison of two methods for segmentation of functional volumes in radiotherapy planning of lung cancer patients.
This study aims to compare the FL volumes identified by both methods. MATERIAL AND METHODS: Thirty lung cancer patients had a 4D and Q-SPECT prior to treatment. Seventeen of these patients also had a ventilation SPECT (V-SPECT). FL sub-volumes were segmented automatically, using cut-off values. The volumes were compared in terms of overlap fraction (OF) relative to the minimal volume, and intersection fraction (IF) of the FL volume relative to the total lung volume (V Lung). RESULTS: Cut-off values suggested in literature for Q-SPECT and 4D-V resulted in volumes differing in size by a median 18% [6%;31%], and a m...
Source: Acta Oncologica - February 1, 2021 Category: Cancer & Oncology Authors: Nyeng TB, Møller DS, Farr K, Kramer S, Khalil AA, Grau C, Hoffmann L Tags: Acta Oncol Source Type: research